Please ensure Javascript is enabled for purposes of website accessibility

Foolish Forecast: Boning Up on Zimmer

By Rich Smith – Updated Nov 15, 2016 at 6:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Views you can use to get clues on tomorrow's news.

Americans are living longer -- and that's great news for Zimmer (NYSE:ZMH). As for how great, we'll be learning the latest news on that front on Monday, when the maker of replacements for our osteo-porous parts reports its earnings numbers for Q4 and all of 2005.

Wall Street Wisdom:

  • General consensus. Zimmer's positioning at the crest of a demographic tide hasn't gone unnoticed on Wall Street, where a full two dozen analysts spend their waking hours tracking the company's progress. Of these learned souls, 15 rate the company a "buy," with the rest counseling either "hold" or "sell."
  • Revenues. Analysts predict that Zimmer will report 6% sales growth to $849 million tomorrow.
  • Earnings. Profits are believed to have hit $0.83 per share in Q4 2005, a 17% increase in comparison with the year-ago quarter.

Margin watch:
Zimmer's margins are on a three-pronged march upwards, with gross margins rising gradually, operating margins a bit faster, and net margins faster still.

Margins %

6/04

9/04

12/04

3/05

6/05

9/05

Gross

74.8

75.2

75.8

76.5

77.0

77.3

Op.

29.5

29.2

30.3

31.4

32.3

33.1

Net

13.0

13.1

18.2

20.1

21.8

22.6

All data courtesy of Capital IQ, a division of Standard & Poors. Data reflects trailing-12-month performance for the quarters ending in the named months.

Valuation metrics:
With its margins as high as they are, and rising as steadily as they are, you won't be surprised to hear that Zimmer's shares command premium prices. The shares currently trade for 23 times trailing earnings despite the prediction that the company will grow profits at 16.5% per annum over the long term. On a price-to- free cash flow basis, Zimmer looks pricier still, trading at 27 times free cash flow.

Competitors:
Compared with its competitors, though, Zimmer's share price looks pretty much in the middle of the road. Slower-growing Biomet (NASDAQ:BMET) trades at about the same earnings multiple, while faster-growing Stryker (NYSE:SYK) commands about a 20% premium to Zimmer.

Fool contributorRich Smithdoes not own shares of any company named above.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Stryker Corporation Stock Quote
Stryker Corporation
SYK
$206.93 (-0.93%) $-1.95

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.